Hybridoma technology has revolutionized the diagnosis of human disease. Owing to the unique specificity of monoclonal antibodies (MABs) of murine origin, hundreds of highly sensitive, accurate in vitro diagnostic tests have been developed for clinical laboratory and athome use. Major research efforts are now underway to exploit this specificity for direct therapeutic purposes: MABs are being used by themselves in treating lymphomas, and in conjugated form with radionuclides, toxins, and chemotherapeutic drugs to treat a variety of tumors. Human MABs now are being tested in tumor imaging and for treatment of infectious diseases. New technologies have been developed to alter the genetic structure of MABs (eg, chimeric antibodies) to increase their treatment efficacy. As development of therapeutic uses for these reagents continues and, especially, as they receive approval for general clinical use, hundreds of kilograms per year will have to be produced. This paper reviews some of the recent developments in this area and describes two novel technologies that have been developed for large-scale cultivation of hybridoma cells.
KöhlerGMilsteinC. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature1975; 256: 495–7
2.
WilkinsonJM. Monoclonal antibodies in agriculture. Span1985; 28: 89–91
3.
StokesCR. Monoclonal antibodies: The practical aspects as applied to immunology and antisera production. In: RossDBSellersLS, eds. New biotechnology for animal health and production. Association of Veterinarians in Industry. Royal College of Veterinary Surgeons, London, 1984: 65
4.
HillCRBirchJRBentonC. Bulk production of monoclonal antibodies in fermenters. In: Bioactive microbial products III — Downstream processing. Special publication of the Society for General Microbiology. New York: Academic Press, 1984.
5.
BoschAMGStevensWSchuursASchoenherrOTReolefsHWM. Characteristics of monoclonal antibodies against human chorionic gonadotrophin (hCG). In: PeetersH, ed. Peptides of the biological fluids. Proceedings of the 29th Colloquium, Brussels. Oxford: Pergamon Press, 1983: 837–42
6.
MillerRAMaloneyDGWarnkeRLevyR. Treatment of a B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med1982; 306: 517–22
HoffmanRA. Clinical utility of cell surface antigen detection. Am Biotech Lab1984; 2: 38–50
9.
MachJChatalJLumbrosoJ. Tumor localization in patients by radiolabeled monoclonal antibodies. Cancer Res1983; 43: 5593–600
10.
MurryJRosenblumNSobolR. Radioimaging in malignant melanoma with 131I-labeled monoclonal antibody. Cancer Res1985; 45: 2376–80
11.
BergerH. Myocardial imaging: New radiotracers aid diagnosis. Diagn Imag1987; 1: 78–89
12.
ShimokawaraIImamuraMYamanakaNIschiiYKikuchiK. Identification of lymphocyte subpopulations in human breast cancer tissue and its significance: An immunoperoxidase study with anti-human T and B-cell sera. Cancer1982; 49: 1456–64
13.
ZeromskiJSzmejaZRewersAKruk-ZagajewskaA. Immunofluorescent assessment of tumour infiltrating cells in laryngeal carcinoma. Application of monoclonal antibodies. Acta Otolaryngol (Stockh)1986; 102: 325–32
14.
ChiorazziNWassermanRKendelH. Use of Epstein-Barr virus-transformed B cell lines for the generation of immunoglobulin-producing human B cell hybridomas. J Exp Med1982; 156: 930–5
15.
BurnettKLeungJMarinisJ. Human monoclonal antibodies to defined antigens. In: EngelmanEFoungSLarrickJRaubitschekA, eds. Human hybridomas and monoclonal antibodies. New York: Plenum Press, 1985: 113–33
16.
TengNKaplanHHebertJ. Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci USA1985; 82: 1790–4
17.
HunterKJr.FischerGHemmingVWilsonSHartzmannBWoodyJ. Antibacterial activity of a human monoclonal antibody to Haemophilus influenzae type B capsular polysaccharide. Lancet1982; 2: 798–9
18.
SteinitzMTamirSGoldfarbA. Human anti-pneumococci antibody produced by an Epstein-Barr virus (EBV)-immortalized cell line. J Immunol1984; 132: 877–82
19.
EmanualDGoldJColacinoJLopezCHammerlingU. A human monoclonal antibody to cytomegalovirus (CMV). J Immunol1984; 133: 2202–5
20.
RittsRJr.Ruiz-ArguellesAWeylK. Establishment and characterization of a human non-secreting plasmacytoid cell line and its hybridization with human B cells. Int J Cancer1983; 31: 133–51
UdomsangpetchRLundgrenKBerzinsK. Human monoclonal antibodies to Pf155, a major antigen of malaria parasite Plasmodium falciparum. Science1986; 231: 57–9
23.
SchoenfeldYRauchJMassicotteH. Polyspecificity of monoclonal lupus autoantibodies produced by human/human hybridomas. N Engl J Med1983; 24: 414–20
24.
HaskardDArcherJ. The production of human monoclonal autoantibodies from patients with rheumatoid arthritis by the EBV-hybridoma technique. J Immunol Methods1984; 74: 361–7
25.
WrightGLJr., ed. Monoclonal antibodies and cancer. New York: Marcel Dekker, 1984.
26.
BoeheimKSchwarzfurtnerHBoeheimCFreiEIIIBernalSD. Immunohistochemical identification of squamous carcinoma of the head and neck with monoclonal antibody SQM1. Acta Otolaryngol (Stockh)1986; 102: 333–40
27.
MeekerTCLowderJMaloneyDG. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood1985; 65: 1349–63
28.
BroombyMRBrownJPriceBJ. Monoclonal antibodies in the United States: A technical and commercial survey of in-vivo applications (trade mission to the United States supported by the Department of Trade and Industry, UK). Report issued by Inveresk Research International, Musselburgh EH21 7UB, Scotland, September 1986.
29.
DillmanRShawlerDDillmanJRoystonI. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol1984; 2: 881–91
30.
ShawlerDBartholemewRSmithLDillmanR. Human immune response to multiple injections of murine monoclonal IgG1. J Immunol1985; 135: 1530–5
31.
OstbergLPurschE. Human X (mouse x human) hybridomas stably producing human antibodies. Hybridoma1983; 2: 361–7
32.
GlassyMHandleyHHagiwaraHRoystonI. UC-729-6, a human lymphoblastoid B-cell line useful for generating antibody-secreting human/human hybridomas. Proc Natl Acad Sci USA1983; 80: 6327–31
33.
LarrickJTruittKRaubitschekASenykGWangJ. Characterization of human hybridomas secreting antibody to tetanus toxoid. Proc Natl Acad Sci USA1983; 80: 6376–80
34.
MorrisonS. Transfectomas provide novel chimaeric antibodies. Science1985; 229: 1202–7
35.
JonesPTDearPHFooteJNeubergerMSWinterG. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature1986; 321: 522–5
36.
ChiorazziN. Human monoclonal antibodies as probes to study autoimmune and allergic disorders. Biotechnology1986; 4: 210–8
37.
BirchJRThompsonPWLambertKBorastonR. The large scale cultivation of hybridoma cells producing monoclonal antibodies. Abstract of presentation at the meeting of the American Chemical Society, Philadelphia, 1984. Available from Celltech Ltd, 244-250 Bath Rd, Slough, Berkshire SL1 4DY, England
38.
HopkinsonJ. Hollow fiber cell culture systems for economical cell-product manufacturing. Biotechnology1985; 3: 225–30
39.
GruenbergMLWalkerRD. A new technique for controlled delivery of biochemical regulatory agents to isolated tissue in culture. BioTechniques1983; 1: 87–9
40.
PosillicoEG. Microencapsulation technology for large-scale antibody production. Biotechnology1986; 4: 114–7
